BXP vs LAB · rev $3.48B vs rev $174.4M
Boston Properties Inc (BXP) versus Standard Biotools Inc (LAB) — a side-by-side from cached financials, not a winner call.
Boston Properties Inc (BXP) is a reit - office company listed on US.
Standard Biotools Inc (LAB) is a medical devices company listed on NASDAQ.
Latest reported BXP revenue for 2025-12-31 was $3.48B. Net income was $276.8M. Revenue was up 2.2% from 2024-12-31 to 2025-12-31. BXP currently screens at market cap $12.12B.
Latest reported LAB revenue for 2024-12-31 was $174.4M. Net income was -$138.9M. Revenue was up 64.0% from 2023-12-31 to 2024-12-31. LAB currently screens at market cap $317.1M.
BXP currently screens at market cap $12.12B. LAB currently screens at market cap $317.1M.
Not investment advice. Open the BXP and LAB stock pages for the full models.
Not investment advice.